Agency News

Home

New Delhi, April 16, 2025: One of the biggest BSE-listed (539528) Aayush Wellness Limited, a trusted name in the nutraceutical industry, has announced its strategic foray into the diagnostics space as part of its next growth phase, driven by the innovative Genome Testing technology. India's diagnostics industry is projected to reach $25 billion by 2028, with the potential to grow up to $40 billion, while the global diagnostics market is expected to grow to $272.98 billion by 2032.
This expansion and the new Genome Testing technology are expected to diversify the company's business model and tap into India’s booming preventive healthcare market, reinforcing its commitment to holistic wellness without limiting it to its current offerings.
Aayush Wellness has been steadily increasing its returns with recent export orders, including a 3 million deal with Singapore-based Cosmos Holdings. This latest development in diagnostics marks a significant pivot. Aayush Wellness aims to build integrated health solutions that combine nutrition, diagnostics, and technology, offering customers a more complete path to well-being.
Founded in 1989 and certified with ISO 9000 and 22000, Aayush Wellness (BSE code: 539528) specialises in advanced health and wellness solutions. As an advanced nutrition company, it has created a name for itself within the health and wellness industry. Its steady expansion into international markets, including Africa and Southeast Asia, product innovation, and a solid domestic footprint make Aayush Wellness an attractive proposition for investors.
With consistent revenue growth and now a foothold in diagnostics with the new-age DNA wellness testing technology, the company is well-positioned to deliver long-term shareholder value, making it a promising player for investors seeking opportunities in the future of integrated healthcare.
Tags
Aayush Wellness
Investment in Healthcare
DNA Wellness Testing
Stocks in Healthcare
Automobile

New Delhi, April 16, 2025: One of the biggest BSE-listed (539528) Aayush Wellness Limited, a trusted name in the nutraceutical industry, has announced its strategic foray into the diagnostics space as part of its next growth phase, driven by the innovative Genome Testing technology. India's diagnostics industry is projected to reach $25 billion by 2028, with the potential to grow up to $40 billion, while the global diagnostics market is expected to grow to $272.98 billion by 2032.
This expansion and the new Genome Testing technology are expected to diversify the company's business model and tap into India’s booming preventive healthcare market, reinforcing its commitment to holistic wellness without limiting it to its current offerings.
Aayush Wellness has been steadily increasing its returns with recent export orders, including a 3 million deal with Singapore-based Cosmos Holdings. This latest development in diagnostics marks a significant pivot. Aayush Wellness aims to build integrated health solutions that combine nutrition, diagnostics, and technology, offering customers a more complete path to well-being.
Founded in 1989 and certified with ISO 9000 and 22000, Aayush Wellness (BSE code: 539528) specialises in advanced health and wellness solutions. As an advanced nutrition company, it has created a name for itself within the health and wellness industry. Its steady expansion into international markets, including Africa and Southeast Asia, product innovation, and a solid domestic footprint make Aayush Wellness an attractive proposition for investors.
With consistent revenue growth and now a foothold in diagnostics with the new-age DNA wellness testing technology, the company is well-positioned to deliver long-term shareholder value, making it a promising player for investors seeking opportunities in the future of integrated healthcare.
Tags
Aayush Wellness
Investment in Healthcare
DNA Wellness Testing
Stocks in Healthcare
Business & Finance

New Delhi, April 16, 2025: One of the biggest BSE-listed (539528) Aayush Wellness Limited, a trusted name in the nutraceutical industry, has announced its strategic foray into the diagnostics space as part of its next growth phase, driven by the innovative Genome Testing technology. India's diagnostics industry is projected to reach $25 billion by 2028, with the potential to grow up to $40 billion, while the global diagnostics market is expected to grow to $272.98 billion by 2032.
This expansion and the new Genome Testing technology are expected to diversify the company's business model and tap into India’s booming preventive healthcare market, reinforcing its commitment to holistic wellness without limiting it to its current offerings.
Aayush Wellness has been steadily increasing its returns with recent export orders, including a 3 million deal with Singapore-based Cosmos Holdings. This latest development in diagnostics marks a significant pivot. Aayush Wellness aims to build integrated health solutions that combine nutrition, diagnostics, and technology, offering customers a more complete path to well-being.
Founded in 1989 and certified with ISO 9000 and 22000, Aayush Wellness (BSE code: 539528) specialises in advanced health and wellness solutions. As an advanced nutrition company, it has created a name for itself within the health and wellness industry. Its steady expansion into international markets, including Africa and Southeast Asia, product innovation, and a solid domestic footprint make Aayush Wellness an attractive proposition for investors.
With consistent revenue growth and now a foothold in diagnostics with the new-age DNA wellness testing technology, the company is well-positioned to deliver long-term shareholder value, making it a promising player for investors seeking opportunities in the future of integrated healthcare.
Tags
Aayush Wellness
Investment in Healthcare
DNA Wellness Testing
Stocks in Healthcare
Education

New Delhi, April 16, 2025: One of the biggest BSE-listed (539528) Aayush Wellness Limited, a trusted name in the nutraceutical industry, has announced its strategic foray into the diagnostics space as part of its next growth phase, driven by the innovative Genome Testing technology. India's diagnostics industry is projected to reach $25 billion by 2028, with the potential to grow up to $40 billion, while the global diagnostics market is expected to grow to $272.98 billion by 2032.
This expansion and the new Genome Testing technology are expected to diversify the company's business model and tap into India’s booming preventive healthcare market, reinforcing its commitment to holistic wellness without limiting it to its current offerings.
Aayush Wellness has been steadily increasing its returns with recent export orders, including a 3 million deal with Singapore-based Cosmos Holdings. This latest development in diagnostics marks a significant pivot. Aayush Wellness aims to build integrated health solutions that combine nutrition, diagnostics, and technology, offering customers a more complete path to well-being.
Founded in 1989 and certified with ISO 9000 and 22000, Aayush Wellness (BSE code: 539528) specialises in advanced health and wellness solutions. As an advanced nutrition company, it has created a name for itself within the health and wellness industry. Its steady expansion into international markets, including Africa and Southeast Asia, product innovation, and a solid domestic footprint make Aayush Wellness an attractive proposition for investors.
With consistent revenue growth and now a foothold in diagnostics with the new-age DNA wellness testing technology, the company is well-positioned to deliver long-term shareholder value, making it a promising player for investors seeking opportunities in the future of integrated healthcare.
Tags
Aayush Wellness
Investment in Healthcare
DNA Wellness Testing
Stocks in Healthcare
Fashion

New Delhi, April 16, 2025: One of the biggest BSE-listed (539528) Aayush Wellness Limited, a trusted name in the nutraceutical industry, has announced its strategic foray into the diagnostics space as part of its next growth phase, driven by the innovative Genome Testing technology. India's diagnostics industry is projected to reach $25 billion by 2028, with the potential to grow up to $40 billion, while the global diagnostics market is expected to grow to $272.98 billion by 2032.
This expansion and the new Genome Testing technology are expected to diversify the company's business model and tap into India’s booming preventive healthcare market, reinforcing its commitment to holistic wellness without limiting it to its current offerings.
Aayush Wellness has been steadily increasing its returns with recent export orders, including a 3 million deal with Singapore-based Cosmos Holdings. This latest development in diagnostics marks a significant pivot. Aayush Wellness aims to build integrated health solutions that combine nutrition, diagnostics, and technology, offering customers a more complete path to well-being.
Founded in 1989 and certified with ISO 9000 and 22000, Aayush Wellness (BSE code: 539528) specialises in advanced health and wellness solutions. As an advanced nutrition company, it has created a name for itself within the health and wellness industry. Its steady expansion into international markets, including Africa and Southeast Asia, product innovation, and a solid domestic footprint make Aayush Wellness an attractive proposition for investors.
With consistent revenue growth and now a foothold in diagnostics with the new-age DNA wellness testing technology, the company is well-positioned to deliver long-term shareholder value, making it a promising player for investors seeking opportunities in the future of integrated healthcare.
Tags
Aayush Wellness
Investment in Healthcare
DNA Wellness Testing
Stocks in Healthcare
Health

New Delhi, April 16, 2025: One of the biggest BSE-listed (539528) Aayush Wellness Limited, a trusted name in the nutraceutical industry, has announced its strategic foray into the diagnostics space as part of its next growth phase, driven by the innovative Genome Testing technology. India's diagnostics industry is projected to reach $25 billion by 2028, with the potential to grow up to $40 billion, while the global diagnostics market is expected to grow to $272.98 billion by 2032.
This expansion and the new Genome Testing technology are expected to diversify the company's business model and tap into India’s booming preventive healthcare market, reinforcing its commitment to holistic wellness without limiting it to its current offerings.
Aayush Wellness has been steadily increasing its returns with recent export orders, including a 3 million deal with Singapore-based Cosmos Holdings. This latest development in diagnostics marks a significant pivot. Aayush Wellness aims to build integrated health solutions that combine nutrition, diagnostics, and technology, offering customers a more complete path to well-being.
Founded in 1989 and certified with ISO 9000 and 22000, Aayush Wellness (BSE code: 539528) specialises in advanced health and wellness solutions. As an advanced nutrition company, it has created a name for itself within the health and wellness industry. Its steady expansion into international markets, including Africa and Southeast Asia, product innovation, and a solid domestic footprint make Aayush Wellness an attractive proposition for investors.
With consistent revenue growth and now a foothold in diagnostics with the new-age DNA wellness testing technology, the company is well-positioned to deliver long-term shareholder value, making it a promising player for investors seeking opportunities in the future of integrated healthcare.
Tags
Aayush Wellness
Investment in Healthcare
DNA Wellness Testing
Stocks in Healthcare
Home & Garden

New Delhi, April 16, 2025: One of the biggest BSE-listed (539528) Aayush Wellness Limited, a trusted name in the nutraceutical industry, has announced its strategic foray into the diagnostics space as part of its next growth phase, driven by the innovative Genome Testing technology. India's diagnostics industry is projected to reach $25 billion by 2028, with the potential to grow up to $40 billion, while the global diagnostics market is expected to grow to $272.98 billion by 2032.
This expansion and the new Genome Testing technology are expected to diversify the company's business model and tap into India’s booming preventive healthcare market, reinforcing its commitment to holistic wellness without limiting it to its current offerings.
Aayush Wellness has been steadily increasing its returns with recent export orders, including a 3 million deal with Singapore-based Cosmos Holdings. This latest development in diagnostics marks a significant pivot. Aayush Wellness aims to build integrated health solutions that combine nutrition, diagnostics, and technology, offering customers a more complete path to well-being.
Founded in 1989 and certified with ISO 9000 and 22000, Aayush Wellness (BSE code: 539528) specialises in advanced health and wellness solutions. As an advanced nutrition company, it has created a name for itself within the health and wellness industry. Its steady expansion into international markets, including Africa and Southeast Asia, product innovation, and a solid domestic footprint make Aayush Wellness an attractive proposition for investors.
With consistent revenue growth and now a foothold in diagnostics with the new-age DNA wellness testing technology, the company is well-positioned to deliver long-term shareholder value, making it a promising player for investors seeking opportunities in the future of integrated healthcare.
Tags
Aayush Wellness
Investment in Healthcare
DNA Wellness Testing
Stocks in Healthcare
Job

New Delhi, April 16, 2025: One of the biggest BSE-listed (539528) Aayush Wellness Limited, a trusted name in the nutraceutical industry, has announced its strategic foray into the diagnostics space as part of its next growth phase, driven by the innovative Genome Testing technology. India's diagnostics industry is projected to reach $25 billion by 2028, with the potential to grow up to $40 billion, while the global diagnostics market is expected to grow to $272.98 billion by 2032.
This expansion and the new Genome Testing technology are expected to diversify the company's business model and tap into India’s booming preventive healthcare market, reinforcing its commitment to holistic wellness without limiting it to its current offerings.
Aayush Wellness has been steadily increasing its returns with recent export orders, including a 3 million deal with Singapore-based Cosmos Holdings. This latest development in diagnostics marks a significant pivot. Aayush Wellness aims to build integrated health solutions that combine nutrition, diagnostics, and technology, offering customers a more complete path to well-being.
Founded in 1989 and certified with ISO 9000 and 22000, Aayush Wellness (BSE code: 539528) specialises in advanced health and wellness solutions. As an advanced nutrition company, it has created a name for itself within the health and wellness industry. Its steady expansion into international markets, including Africa and Southeast Asia, product innovation, and a solid domestic footprint make Aayush Wellness an attractive proposition for investors.
With consistent revenue growth and now a foothold in diagnostics with the new-age DNA wellness testing technology, the company is well-positioned to deliver long-term shareholder value, making it a promising player for investors seeking opportunities in the future of integrated healthcare.
Tags
Aayush Wellness
Investment in Healthcare
DNA Wellness Testing
Stocks in Healthcare
Tech & Gadgets

New Delhi, April 16, 2025: One of the biggest BSE-listed (539528) Aayush Wellness Limited, a trusted name in the nutraceutical industry, has announced its strategic foray into the diagnostics space as part of its next growth phase, driven by the innovative Genome Testing technology. India's diagnostics industry is projected to reach $25 billion by 2028, with the potential to grow up to $40 billion, while the global diagnostics market is expected to grow to $272.98 billion by 2032.
This expansion and the new Genome Testing technology are expected to diversify the company's business model and tap into India’s booming preventive healthcare market, reinforcing its commitment to holistic wellness without limiting it to its current offerings.
Aayush Wellness has been steadily increasing its returns with recent export orders, including a 3 million deal with Singapore-based Cosmos Holdings. This latest development in diagnostics marks a significant pivot. Aayush Wellness aims to build integrated health solutions that combine nutrition, diagnostics, and technology, offering customers a more complete path to well-being.
Founded in 1989 and certified with ISO 9000 and 22000, Aayush Wellness (BSE code: 539528) specialises in advanced health and wellness solutions. As an advanced nutrition company, it has created a name for itself within the health and wellness industry. Its steady expansion into international markets, including Africa and Southeast Asia, product innovation, and a solid domestic footprint make Aayush Wellness an attractive proposition for investors.
With consistent revenue growth and now a foothold in diagnostics with the new-age DNA wellness testing technology, the company is well-positioned to deliver long-term shareholder value, making it a promising player for investors seeking opportunities in the future of integrated healthcare.
Tags
Aayush Wellness
Investment in Healthcare
DNA Wellness Testing
Stocks in Healthcare
Travel & Lifestyle

New Delhi, April 16, 2025: One of the biggest BSE-listed (539528) Aayush Wellness Limited, a trusted name in the nutraceutical industry, has announced its strategic foray into the diagnostics space as part of its next growth phase, driven by the innovative Genome Testing technology. India's diagnostics industry is projected to reach $25 billion by 2028, with the potential to grow up to $40 billion, while the global diagnostics market is expected to grow to $272.98 billion by 2032.
This expansion and the new Genome Testing technology are expected to diversify the company's business model and tap into India’s booming preventive healthcare market, reinforcing its commitment to holistic wellness without limiting it to its current offerings.
Aayush Wellness has been steadily increasing its returns with recent export orders, including a 3 million deal with Singapore-based Cosmos Holdings. This latest development in diagnostics marks a significant pivot. Aayush Wellness aims to build integrated health solutions that combine nutrition, diagnostics, and technology, offering customers a more complete path to well-being.
Founded in 1989 and certified with ISO 9000 and 22000, Aayush Wellness (BSE code: 539528) specialises in advanced health and wellness solutions. As an advanced nutrition company, it has created a name for itself within the health and wellness industry. Its steady expansion into international markets, including Africa and Southeast Asia, product innovation, and a solid domestic footprint make Aayush Wellness an attractive proposition for investors.
With consistent revenue growth and now a foothold in diagnostics with the new-age DNA wellness testing technology, the company is well-positioned to deliver long-term shareholder value, making it a promising player for investors seeking opportunities in the future of integrated healthcare.
Tags
Aayush Wellness
Investment in Healthcare
DNA Wellness Testing
Stocks in Healthcare

Latest post

Renowned Indian Vedic Astrologer & Crystal Healer Samaira Jaisinghani Revolutionizes Astrology with Ancient Wisdom

Plumbex India 2025 Inaugurated in New Delhi

SportsBaazi Introduces ‘Pro Trader and Coach’ Role, Signalling a New Era of Strategic Excellence in Sports Trading

Popular Posts

Allianz Packers and Movers: Expanding Services to Tier 2 & Tier 3 Cities (4145)

Best Tips for Choosing The Best Financial Products (2056)

Expert Institute of Advance Technologies: Pioneering Tech Training (1217)

TOP 10 OUTSTANDING LEADERS TO FOLLOW IN 2024 (1036)

Power Of Prospection For Your Financial Future (1014)

Stay Connected

Category: Agency News

Aayush Wellness Expands Horizons with Strategic Entry into $25 Billion Diagnostic Segment

Banganga Paper Mills Receives Renewed Environmental Certification From MPCB

Quickly check your personal loan EMI with an easy calculator for better financial planning

ANSR Named a Leader in 2025 ISG Provider Lens™ for Global Capability Centers (GCC) Design and Setup

Kalp Studio and MGrow Launch IBM-Certified Blockchain Program with 100% Job Guarantee

Prestigious Fames Awards 2025: A Remarkable Virtual Celebration of Excellence

Dubai Creates a New World Record with the Launch of the World’s Costliest Mocktail at Jimmydixs Restaurant & Lounge, Barcelo Hotel

Well Being Foundation | Paving the Path to Change

Off Kicks Inc’s Rise in India’s Luxury Industry: Stepping Beyond Sneakers

“Shailesh Ramugade: The Heartfelt Doppelgänger of Salman Khan Who’s Redefining Stardom at Bombay Times Fashion Week!”

Popular Post

Allianz Packers and Movers: Expanding Services to Tier 2 & Tier 3 Cities (4145)

Best Tips for Choosing The Best Financial Products (2056)

Expert Institute of Advance Technologies: Pioneering Tech Training (1217)

TOP 10 OUTSTANDING LEADERS TO FOLLOW IN 2024 (1036)

Power Of Prospection For Your Financial Future (1014)

Advertisement

Popular Posts

Allianz Packers and Movers: Expanding Services to Tier 2 & Tier 3 Cities

Best Tips for Choosing The Best Financial Products

Expert Institute of Advance Technologies: Pioneering Tech Training

Find us on Facebook